Barrington Research analyst Michael Petusky upgraded Anika Therapeutics (NASDAQ: ANIK) from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE